Press Release: Giuseppe Pasceri appointed as General Manager for Adevinta in Italy
Italy, 23 october 2019: Adevinta, a global online classifieds company with generalist, real estate, cars, jobs and other internet marketplaces in 16 countries, today announces that Giuseppe Pasceri will succeed Melany Libraro as the new General Manager for Adevinta in Italy, overseeing Subito and InfoJobs.
Giuseppe joined Adevinta Italy in 2018 from the Italian Government Digital Team, bringing extensive experience in digital transformation and user-centered businesses. He most recently served as Chief Product Officer and Chief Technology Officer for Adevinta Italy. Giuseppe has over 25 years of experience in digital businesses, having worked for companies such as Yahoo!, eBay, RCS, Jobrapido and the Italian Government Digital Service.
In his new role, Giuseppe will oversee all aspects of Subito and InfoJobs’ strategy and execution, with the goal to increase Adevinta’s leadership position in Italy and improve our users experience.
“Giuseppe brings a thorough understanding of our users and customers, relentless focus on execution and a growth mindset,” said Ovidiu Solomonov, SVP Global Markets & New Models at Adevinta. “We are confident Giuseppe will lead our Italian businesses to accelerated growth by delivering fantastic products for our users and customers; this will also result in great financial results.”
“We have a unique opportunity to grow our user and content base, and our main priority for 2020 is to create more happy users. We are ready to accelerate our development and improve our products,” said Giuseppe Pasceri.
- End -
Notes to the editor
Adevinta is a global online classifieds company with generalist, real estate, cars, jobs and other internet marketplaces in 16 countries, connecting buyers seeking goods or services with a large base of sellers. Its portfolio spans 36 digital products and websites, attracting 1.5 billion average monthly visits. Leading brands include top-ranked leboncoin in France, InfoJobs and Milanuncios in Spain, and 50% of fast-growing OLX in Brazil.
T: +33 (0) 6 84 30 52 76
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF17.11.2019 16:45:00 CET | Press release
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compared to valsartan1 Entresto, compared to valsartan, demonstrated reduced risk in total heart failure hospitalizations and cardiovascular death in women, compared to men2 Among patients who had been previously hospitalized, those who were screened during or within 30 days of hospitalization showed the greatest treatment effect with Entresto, compared to valsartan3 Safety and tolerability of Entresto, where evaluated, were consistent with previously reported findings1,2,4,5 New analyses follow full results from the PARAGON-HF trial, which show overall treatment effect, despite narrow miss on statistical significance4 The digital press release with multimedia content can be accessed here: https://novartis.gcs-web.com/Novartis-PARAGON-HF-analyses-suggest-Entresto-benefit-beyond-HFrEF Basel, November 17, 2019 — Novartis announced today new subgroup analyses from its
LIDDS Liproca® Depot Phase IIb study results presented at EMUC19 showing both primary and secondary endpoints being met16.11.2019 10:10:00 CET | Press release
UPPSALA, SWEDEN – LIDDS AB (publ) Phase IIb clinical data from the LPC-004 prostate cancer study on LIDDS Liproca® Depot were presented today in an oral session at the 11th European Multidisciplinary Congress on Urological Cancers, EMUC19. The study met both its primary and secondary endpoints as well as demonstrated that a larger proportion of intermediate risk patients, which is the Liproca Depot target group, are PSA responders. The presentation can be accessed through LIDDS webpage and are also attached to this release. The phase IIb results from the LPC-004 prostate cancer study was presented as “Late Breaking News” at EMUC in Vienna on November 16, 2019 by Professor Laurence Klotz, a world leading expert in Active Surveillance of prostate cancer patients. Professor Klotz was one of the LPC-004 study investigators and is Professor at the University of Toronto Division of Urology at the Sunnybrook Health Sciences Centre in Canada. The preliminary data recently released from the pha
AMG Advanced Metallurgical Group N.V. Completes Acquisition of International Specialty Alloys15.11.2019 23:30:00 CET | Press release
Amsterdam, 15 November 2019 --- AMG Advanced Metallurgical Group N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") has finalized the acquisition of the assets of International Specialty Alloys ("ISA"), a leading U.S. producer of titanium master alloys and other binary alloys for the aerospace market, from Kennametal, Inc. The acquisition was previously announced on October 9, 2019 and closed and became effective today. About AMG AMG is a global critical materials company at the forefront of CO2 reduction trends. AMG produces highly engineered specialty metals and mineral products and provides related vacuum furnace systems and services to the transportation, infrastructure, energy, and specialty metals & chemicals end markets. AMG Critical Materials produces aluminum master alloys and powders, ferrovanadium, natural graphite, chromium metal, antimony, lithium, tantalum, niobium and silicon metal. AMG Technologies produces titanium aluminides and titanium alloys for the aerospace market; designs,
New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease15.11.2019 21:06:00 CET | Press release
Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications1 Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.63 vs 2.98) and the annual rate of days hospitalized (4 vs 6.87) in a 52-week study2 Approximately 100,000 people in the United States, most of whom are of African descent, have sickle cell disease3 Approval comes approximately two months ahead of FDA’s priority review action date, allowing Adakveo to be available to patients more quickly Basel, November 15, 2019 – Novartis announced today that the US Food and Drug Administration (FDA) approved Adakveo ® (crizanlizumab), previously known as SEG101, to reduce the frequency of vaso-occlusive crises (VOCs), or pain crises, in adult and pediatric patients aged 16 years and older with sickle cell disease.4 Adakveo represents the first FDA-approved medicine in sickle cell disease that binds to P-selectin –a cell adhesion protein that plays a central r
SFL - Invitation to Presentation of Q3 2019 Results15.11.2019 20:06:00 CET | Press release
SFL Corporation Ltd. ("SFL" or the “Company”) (NYSE: SFL) plans to release its preliminary financial results for the third quarter of 2019 on Thursday, November 21, 2019. SFL plans to host a conference call and webcast for all stakeholders and interested parties on Thursday, November 21, 2019 at 10:00 AM (EST) / 4:00 PM (CET). Relevant material will be available from the Investor Relations section of the Company’s website at www.sflcorp.com on the same day. In order to listen to the presentation you may do one of the following: A: Webcast Visit the Investor Relations section of the Company’s website at www.sflcorp.com and click on the link to "Webcast". The webcast with slideshow will be played live from this platform. To listen to the conference call from the website, you need to have installed Windows Media Player, and you need to have a sound card on your computer. B: Conference Call Participants dial-in details: US Toll Free telephone number +1 866 966 1396 International Dial-in te
Cavotec’s Nomination Committee ahead of Annual General Meeting 202015.11.2019 18:00:00 CET | Press release
The Nomination Committee of Cavotec SA (“Cavotec”) consists of members appointed by Cavotec’s Board of Directors, in accordance with Cavotec's Internal Regulations. The composition of the members of the Nomination Committee presented below is in line with the recommendations of the Swedish Corporate Governance Code. The main purpose and responsibility of the Nomination Committee is to present proposals for the election and remuneration of the Chairman and the Board of Directors as well as the Auditors to the Annual General Meeting 2020. The Board of Directors has decided that the four largest shareholders and the Chairman of Cavotec’s Board of Directors shall be represented in the Nomination Committee. On 31 October 2019, the four largest shareholders recorded in the company’s share register were Bure Equity AB (27.1% of the vote), AP4 (9.8% of the vote), Nomina SA (8.1% of the vote) and Founding Shareholders (Stefan Widegren, Lars Hellman and Peter Brandel with families) (11.9 % of th